Amanta Healthcare Announces Q4 and Full Year FY26 Results, Reports 42% YoY Profit Growth

Amanta Healthcare Announces Q4 and Full Year FY26 Results, Reports 42% YoY Profit Growth​

Amanta Healthcare Limited today announced its unaudited financial results for the quarter and full year ended March 31, 2026. The company reported significant growth in profitability, with a 42% year-over-year (YoY) increase in Profit After Tax (PAT) for the financial year 2026.

The financial performance for Q4FY26 and FY26 showed consistent revenue momentum, supported by operational improvements.

Financial Performance Overview​

The key financial metrics for the company for the respective periods are detailed in the table below (Figures in Rs. in Cr.):

Key Operational Highlights​

Amanta Healthcare reported several operational highlights for the quarter and year.

The company maintained a sustained revenue trajectory, with Q4FY26 revenue standing at INR 76.99 Cr, reflecting a 6.8% YoY growth. For the full financial year 2026, revenue reached INR 287.68 Cr, marking a 4.7% YoY increase.

Operational discipline was evident as EBITDA for Q4FY26 was recorded at INR 16.61 Cr with margins at 22%. Year-over-year, FY26 EBITDA increased by 3.6% to INR 63.23 Cr, with margins improving to 22%, highlighting effective cost control.

Profitability strengthened robustly, with Net Profit for Q4FY26 rising to INR 5.53 Cr, up 28.0% YoY. Full-year PAT saw a substantial growth of 41.7% YoY, reaching INR 14.88 Cr. This strong profitability momentum was primarily attributed to a decrease in finance cost. The PAT margin improved to 7% for Q4FY26, and 5% for FY26, up from 6% and 4% respectively in Q4FY25 and FY25.

Management Commentary​

Bhavesh Patel, Chairman & Managing Director of Amanta Healthcare Limited, commented on the performance, stating that FY26 was characterized by consistent progress and disciplined execution. He highlighted that while the company reported revenue of ₹287.68 crore, showing 5% YoY growth, the PAT grew strongly by 42% YoY to ₹15 crore.

Mr. Patel added that the strong earnings quality was supported by improved operating leverage and lower finance costs. For the quarter, the revenue stood at ₹77 crore, up 7% YoY, while PAT increased 28% YoY to ₹5.5 crore.

Looking ahead, Amanta Healthcare plans to focus on scaling high-margin SteriPort and SVP capacities. The company also aims to expand its presence across domestic and export markets while enhancing operational efficiencies through strategic initiatives like its captive solar power project. Amanta believes its combination of differentiated manufacturing technologies, a growing product portfolio, and ongoing capacity expansion positions it well for sustainable growth.

About Amanta Healthcare Limited​

Amanta is a pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenterals (LVPs and SVPs). Utilizing advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the company services six therapeutic segments. Its products include IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions, with container volumes ranging from 2 ml to 1000 ml. The company is led by its Promoter & CMD, Mr. Bhavesh Patel.

AMANTA Stock Price Movement​

Today, Amanta Healthcare Limited shares edged higher, closing at ₹132.00, recording a robust 4.91% gain. The stock traded on 101,401 shares, signaling strong buyer interest throughout the day.